Milica Margeta is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 52 publications with 1,181 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Huntington Ave
Boston, MA 021156303
Telephone
617-936-6156Registry record last updated 8 Aug 2016.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- IDORSIA PHARMACEUTICALS US INCProgram year20231 payment
- Alcon Research LLCProgram year20222 payments$75,608openpaymentsdata.cms.gov ↗
- Alcon Vision LLCProgram year20223 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
83.6%Prostaglandin Analog37.9%Latanoprost84%Lumigan8%Tafluprost6%Travoprost2%Part D<11 patientsCarbonic Anhydrase Inhibitor23.5%Dorzolamide-Timolol88%Dorzolamide Hcl10%Acetazolamide3%Part D<11 patients+ 3 more classes in this area
Cardiovascular
12.8%Beta blocker12.8%Timolol Maleate100%Part D≥64 patientsNervous system
3%Cholinergic Receptor Agonist3%Pilocarpine Hcl100%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Mechanisms of microglial neuroinflammatory response in glaucoma
Schepens Eye Research Institute
FY2026$492,500R01EY035312 - Mechanisms of microglial neuroinflammatory response in glaucoma
Schepens Eye Research Institute
FY2025$418,625R01EY035312 - Mechanisms of microglial neuroinflammatory response in glaucoma
Schepens Eye Research Institute
FY2024$492,500R01EY035312
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Dean Eliott, MD
Massachusetts Eye and Ear Infirmary
Leo Kim, MD
Massachusetts Eye and Ear Infirmary
Daniel Liebman, MD
Massachusetts Eye and Ear Infirmary
Reza Dana, MD, MSE, MPH
Massachusetts Eye and Ear Infirmary
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”